{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:04:03Z","timestamp":1787652243810,"version":"build-2736575974"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pheochromocytomas and paragangliomas (PCC\/PGL) are rare neuroendocrine tumors and can secrete catecholamine. Previous studies have found that SDHB immunohistochemistry (IHC) can predict SDHB germline gene mutation, and SDHB mutation is closely associated with tumor progression and metastasis. This study aimed to clarify the potential effect of SDHB IHC as a predictive marker for tumor progression in PCC\/PGL patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included PCC\/PGL patients diagnosed in Ruijin Hospital, Shanghai Jiao Tong University School of Medicine from 2002 to 2014 for retrospective analysis and discovered that SDHB (-) staining patients had poorer prognoses. Then we examined SDHB protein expression by IHC on all tumors in the prospective series, which was composed of patients from 2015 to 2020 in our center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the retrospective series, the median follow-up was 167 months, and during follow-up, 14.4% (38\/264) patients developed metastasis or recurrence, and 8.0% (22\/274) patients died. Retrospective analysis revealed that 66.7% (6\/9) of participants in the SDHB (-) group and 15.7% (40\/255) of those in the SDHB (+) group developed progressive tumors (OR: 10.75, 95% CI: 2.72-52.60, P=0.001), and SDHB (-) was independently associated with poor outcomes after adjusting by other clinicopathological parameters (OR: 11.68, 95% CI: 2.58-64.45, P=0.002). SDHB (-) patients had shorter disease-free survival (DFS) and overall survival (OS) (P&amp;lt;0.001) and SDHB (-) was significantly associated with shorter median DFS (HR: 6.89, 95% CI: 2.41-19.70, P&amp;lt;0.001) in multivariate cox proportional hazard analysis. In the prospective series, the median follow-up was 28 months, 4.7% (10\/213) patients developed metastasis or recurrence, and 0.5% (1\/217) patient died. For the prospective analysis, 18.8% (3\/16) of participants in the SDHB (-) group had progressive tumors compared with 3.6% (7\/197) in the SDHB (+) group (RR: 5.28, 95% CI: 1.51-18.47, P=0.009), statistical significance remained (RR: 3.35, 95% CI: 1.20-9.38, P=0.021) after adjusting for other clinicopathological factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings demonstrated patients with SDHB (-) tumors had a higher possibility of poor outcomes, and SDHB IHC can be regarded as an independent biomarker of prognosis in PCC\/PGL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2023.1121397","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T02:52:11Z","timestamp":1678935131000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Tingwei","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"B1","volume-title":"WHO classification of tumours: Pathology and genetics of tumours of endocrine organs","author":"DeLellis RA","year":"2004"},{"key":"B2","volume-title":"WHO classification of tumours: pathology and genetics of tumours of endocrine organs","author":"Loyd","year":"2017"},{"key":"B3","volume-title":"WHO classification of endocrine and neuroendocrine tumours","year":"2022"},{"key":"B4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1530\/ERC-13-0415","article-title":"Long-term prognosis of patients with pediatric pheochromocytoma","volume":"21","author":"Bausch","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13357","article-title":"Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas","volume":"87","author":"Zhong","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-6074-1","article-title":"Clinical predictors of malignancy in patients with pheochromocytoma and paraganglioma","volume":"24","author":"Dhir","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1946","article-title":"Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: Primary tumor size and primary tumor location as prognostic indicators","volume":"96","author":"Ayala-Ramirez","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.8898","article-title":"Comparison of pheochromocytoma-specific morbidity and mortality among adults with bilateral pheochromocytomas undergoing total adrenalectomy vs cortical-sparing adrenalectomy","volume":"2","author":"Neumann","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02411","article-title":"Positive impact of genetic test on the management and outcome of patients with paraganglioma and\/or pheochromocytoma","volume":"104","author":"Buffet","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa608","article-title":"Predicting metastatic potential in pheochromocytoma and paraganglioma: A comparison of PASS and GAPP scoring systems","volume":"105","author":"Wachtel","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13434","article-title":"Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis","volume":"87","author":"Hamidi","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0086","article-title":"SDHB mutation carriers with malignant pheochromocytoma respond better to CVD","volume":"24","author":"Fishbein","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-16-0033","article-title":"European Society of endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma","volume":"174","author":"Plouin","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: A position statement and consensus of the working group on endocrine hypertension of the European society of hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J Hypertens"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: A clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2018.05.001","article-title":"A clinical prediction model to estimate the metastatic potential of pheochromocytoma\/paraganglioma: ASES score","volume":"164","author":"Cho","year":"2018","journal-title":"Surgery"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02553-5","article-title":"COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas","volume":"474","author":"Pierre","year":"2019","journal-title":"Virchows Arch"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101416","DOI":"10.1016\/j.beem.2020.101416","article-title":"An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma","volume":"34","author":"Buffet","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2016.05.050","article-title":"SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma","volume":"161","author":"Assadipour","year":"2017","journal-title":"Surgery"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2019-106324","article-title":"Risk of metastatic pheochromocytoma and paraganglioma in SDHx mutation carriers: A systematic review and updated meta-analysis","volume":"57","author":"Lee","year":"2020","journal-title":"J Med Genet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"105949","DOI":"10.1016\/j.biocel.2021.105949","article-title":"MITOCHONDRIA: Succinate dehydrogenase subunit b-associated phaeochromocytoma and paraganglioma","volume":"134","author":"Dona","year":"2021","journal-title":"Int J Biochem Cell Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.41","article-title":"SDHB\/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: A multicenter interobserver variation analysis using virtual microscopy: A multinational study of the European network for the study of adrenal tumors (ENS@T)","volume":"28","author":"Papathomas","year":"2015","journal-title":"Mod Pathol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70164-0","article-title":"An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: A retrospective and prospective analysis","volume":"10","author":"van Nederveen","year":"2009","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/his.13277","article-title":"Succinate dehydrogenase (SDH)-deficient neoplasia","volume":"72","author":"Gill","year":"2018","journal-title":"Histopathology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000534","article-title":"Urinary bladder paragangliomas: How immunohistochemistry can assist to identify patients with SDHB germline and somatic mutations","volume":"39","author":"Giubellino","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"268ra177","DOI":"10.1126\/scitranslmed.3009961","article-title":"Recurrent epimutation of SDHC in gastrointestinal stromal tumors","volume":"6","author":"Killian","year":"2014","journal-title":"Sci Transl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0254","article-title":"Aberrant DNA hypermethylation of SDHC: A novel mechanism of tumor development in Carney triad","volume":"21","author":"Haller","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0316","article-title":"SDHB loss predicts malignancy in pheochromocytomas\/sympathethic paragangliomas, but not through hypoxia signalling","volume":"17","author":"Blank","year":"2010","journal-title":"Endocr Relat Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2021.22.6.1721","article-title":"Succinate dehydrogenase complex iron sulfur subunit b (SDHB) immunohistochemistry in pheochromocytoma, head and neck paraganglioma, thoraco-Abdomino-Pelvic paragangliomas: Is it a good idea to use in routine work","volume":"22","author":"Gul","year":"2021","journal-title":"Asian Pac J Cancer Prev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.882906","article-title":"Value of immunohistochemical expression of apelin, succinate dehydrogenase b, chromogranin b, human epidermal growth factor receptor-2, contactin 4, and succinyl-CoA synthetase subunit beta in differentiating metastatic from non-metastatic pheochromocytoma and paraganglioma","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187398","article-title":"Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma","volume":"12","author":"Koh","year":"2017","journal-title":"PloS One"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-40618-3_77","article-title":"Adrenal-neuroendocrine tumors","volume":"8","author":"Jimenez","year":"2017","journal-title":"AJCC Cancer staging manual"},{"key":"B35","doi-asserted-by":"publisher","first-page":"8850990","DOI":"10.1155\/2021\/8850990","article-title":"Expression of glutamine metabolism-related and amino acid transporter proteins in adrenal cortical neoplasms and pheochromocytomas","volume":"2021","author":"Kim","year":"2021","journal-title":"Dis Markers"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11381","article-title":"Potential pitfalls of SDH immunohistochemical detection in paragangliomas and phaeochromocytomas harbouring germline SDHx gene mutation","volume":"37","author":"Santi","year":"2017","journal-title":"Anticancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1096\/fj.12-210146","article-title":"Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function","volume":"26","author":"Yang","year":"2012","journal-title":"FASEB J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13019","article-title":"ERBB-2 overexpression as a risk factor for malignant phaeochromocytomas and paraganglinomas","volume":"84","author":"Wang","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/biology10070677","article-title":"Efficacy of immunohistochemistry for SDHB in the screening of hereditary pheochromocytoma-paraganglioma","volume":"10","author":"Choi","year":"2021","journal-title":"Biol (Basel)"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1121397\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T02:52:14Z","timestamp":1678935134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1121397\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":39,"alternative-id":["10.3389\/fendo.2023.1121397"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1121397","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]},"article-number":"1121397"}}